Groww Logo
Home>US Stocks>Alexion Pharmaceuticals, Inc.
A

Alexion Pharmaceuticals, Inc.

Healthcare
$182.50
+ $3.05 (1.70%) 1D
1D
1W
1M
1Y
3Y
5Y

Performance

Today’s Low
$
    Today’s High
    $
    52W Low
    $
      52W High
      $
      Open PricePrev. CloseVolumeAvg. Volume
      $181.04$182.5036,200,075

      Fundamentals

      Market Cap$40.33B
      P/B Ratio3.2
      P/E Ratio59.2
      Enterprise Value$39.60B
      Div. Yield0.00%
      Book Value52.94
      EPS(TTM)2.74
      ROE5.40%
      Understand Fundamentals

      About the Company

      Alexion Pharmaceutical, Inc. (NYSE: ALXN) is an American biopharmaceutical company founded in the year 1992. It conducts extensive researches on the immune system and autoimmune diseases. It is headquartered in Massachusetts, US. In 2011, with a mark
      Alexion Pharmaceutical, Inc. (NYSE: ALXN) is an American biopharmaceutical company founded in the year 1992. It conducts extensive researches on the immune system and autoimmune diseases. It is headquartered in Massachusetts, US. In 2011, with a market value of $8.5 million, Alexion was added to the NASDAQ-100. ALXN shares reached their all-time high closing price of $207.84 on July 23rd, 2015. As of 2020, the company’s net worth was $24.71 billion. Alexion Pharmaceutical, Inc. is best known for its development of Soliris, a medicine used to treat rare disorders such as aHUS and PNH. Soliris received approval from the US Food and Drug Administration (FDA) in 2007. In 2010, Germany saw an outbreak of Haemolytic-Uremic Syndrome (HUS) and Soliris was considered as a treatment option. The company also offers speciality drugs for other rare diseases such as gMG, HPP, LAL-D and NMOSD. In addition to Soliris, the company also developed Strensiq – a drug that treats Hypophosphatasia, a rare metabolic disorder. Alexion also acquired Kanuma, a medication for Lysosomal Acid Lipase Deficiency, a fatal genetic disorder. The company’s research segment focuses on the core therapeutic areas of neurology, haematology, metabolics, nephrology and cardiology. Over the years, Alexion has acquired several leading companies. Some notable acquisitions include Proliferon Inc. in 2000, Enobia Pharma Corp in 2011, Syntimmune in 2018, Achillion Pharmaceuticals in 2019, and Portola in the year 2020. It received the Judge’s Prize in the 2018 Best Practices Award by Bio-IT World for its SmartPanel platform. The company was awarded the 2009 Prix Galien (The Galien Prize) for its Soliris medication. As of 2019, Alexion Pharmaceutical, Inc. ranked 41 in Fortune’s list of Future 50. In 2020, Alexion was also recognised by OSHA (Occupational Safety and Health Administration) for its commitment to workplace health and security. The company ranks 796 on Forbes’ list of Global 2000 2020 companies. It was also included in Forbes’ list of World Best Employers in 2020. As of 2020, the company operates in several regions worldwide like North America, Europe, Middle-East, Latin America, and the Asia-Pacific, among others.
      ...Read more
      OrganisationAlexion Pharmaceuticals, Inc.
      IndustryBiotechnology
      HeadQuartersBoston, MA

      Company Financials

      *All values are in Million $
      No Graph Data To Display
      Quarterly
      Yearly
      See Details

      FAQs on Alexion Pharmaceuticals, Inc.

      Can I Buy Alexion Pharmaceuticals, Inc. Shares in India?

      Yes, Alexion Pharmaceuticals, Inc. shares can be bought in India by opening an international trading account with Groww.

      How to Buy Alexion Pharmaceuticals, Inc. Shares in India?

      One can easily invest in Alexion Pharmaceuticals, Inc. shares from India by: Direct Investment - Opening an international trading account with Groww which includes KYC verification in the US. Your account gets activated in a few minutes to a few hours, after which you can start adding funds in USD balance to buy Alexion Pharmaceuticals, Inc. shares. Indirect Investment - Under this form of investment, you can choose either a Mutual Fund (MF) or an Exchange-Traded Fund (ETF) that invests in global shares and start investing in shares of Alexion Pharmaceuticals, Inc..

      What is the Share Price of Alexion Pharmaceuticals, Inc.?

      The share price of Alexion Pharmaceuticals, Inc. is in Dollars and if you are investing from India, you can always check the INR valuation before investing. The current Alexion Pharmaceuticals, Inc. share price is $182.50 as of 15 May ‘22

      What is the Market Cap of Alexion Pharmaceuticals, Inc.?

      The Alexion Pharmaceuticals, Inc. market cap is $40.33B as of 15 May ‘22

      What is the PE and PB ratio of Alexion Pharmaceuticals, Inc.?

      The PE and PB ratio of Alexion Pharmaceuticals, Inc. is 59.2 and 3.2 as of 15 May ‘22
      ⓒ 2016-2022 Groww. All rights reserved, Built with in India
      MOST POPULAR ON GROWWVERSION - 2.3.7
      STOCK MARKET INDICES:  S&P BSE SENSEX |  S&P BSE 100 |  NIFTY 100 |  NIFTY 50 |  NIFTY MIDCAP 100 |  NIFTY BANK |  NIFTY NEXT 50
      MUTUAL FUNDS COMPANIES:  ICICI PRUDENTIAL |  HDFC |  NIPPON INDIA |  ADITYA BIRLA SUN LIFE |  SBI |  UTI |  FRANKLIN TEMPLETON |  KOTAK MAHINDRA |  IDFC |  DSP |  AXIS |  TATA |  L&T |  SUNDARAM |  PGIM |  INVESCO |  LIC |  JM FINANCIAL |  BARODA PIONEER |  CANARA ROBECO |  HSBC |  IDBI |  INDIABULLS |  MOTILAL OSWAL |  BNP PARIBAS |  MIRAE ASSET |  PRINCIPAL |  BOI AXA |  UNION KBC |  TAURUS |  EDELWEISS |  NAVI |  MAHINDRA |  QUANTUM |  PPFAS |  IIFL |  Quant |  SHRIRAM |  SAHARA |  ITI

      ABOUT GROWW